ID
29058
Description
Study part: Subject Eligibility Screening. A Phase IIIb, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study Of The Efficacy And Safety Of Ranibizumab In Subjects With Subfoveal Choroidal Neovascular (CNV) With Or Without Classic CNV Secondary To Age-Related Macular Degeneration.
Keywords
Versions (1)
- 2/22/18 2/22/18 -
Copyright Holder
Roche
Uploaded on
February 22, 2018
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Subject Eligibility Screening Ranibizumab Age-Related Macular Degeneration FVF3192g
Subject Eligibility Screening
- StudyEvent: ODM
Similar models
Subject Eligibility Screening
- StudyEvent: ODM
C2986440 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,2])
C1705236 (UMLS CUI [1,2])